All In MedTech

FDA Clearance Tracker · P970004-S023

MEDTRONIC INTERSTIM THERAPY FOR URINARY CONTROL STIMULATON DESKTOP SOFTWARE

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jan 23, 2003 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jan 23, 2003

Approved

Time to decision

176 days

Received Jul 31, 2002. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P970004-S023
Device name
MEDTRONIC INTERSTIM THERAPY FOR URINARY CONTROL STIMULATON DESKTOP SOFTWARE
Applicant location
Minneapolis, MN
Received
Jul 31, 2002
Decided
Jan 23, 2003
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P970004

Device type

Device class
Class III
Regulation
21 CFR 876.5270

Every decision under product code EZW

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE MODEL 8870 INTERSTIM APPLICATION SOFTWARE TO OPERATING ON THE MODEL 8840 CLINICIAN PROGRAMMER, USE OF ENHANCED STIMULATION DESKTOP SOFTWARE, AN EXPANDED MEMORY CARD STORAGE, AND UPDATED LABELING. THESE CHANGES ARE USED WITH THE MEDTRONIC INTERSTIM THERAPY FOR URINARY CONTROL, WHICH IS INDICATED FOR THE TREATMENT OF URINARY RETENTION AND THE SYMPTOMS OF OVERACTIVE BLADDER, INCLUDING URINARY URGE INCONTINENCE AND SIGNIFICANT SYMPTOMS OF URGENCY-FREQUENCY ALONE OR IN COMBINATION, IN PATIENTS WHO HAVE FAILED OR COULD NOT TOLERATE MORE CONSERVATIVE TREATMENTS.

Source documents

Other decisions for Medtronic Neuromodulation

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

2 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.